World Heart presses on with "destination therapy" programme
This article was originally published in Clinica
Executive Summary
World Heart is re-launching efforts to take its Novacor heart pump in the US "destination therapy" market for patients who are not eligible for a heart transplant, after gaining FDA clearance to significantly expand a pivotal trial.